MedTrace Logo

Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome

NCT00327132 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 47

Last updated 2016-03-25

No results posted yet for this study

Summary

1. The complete histological and molecular remission rate for antibiotics as 1st-line therapy for Hp-positive early-stage gastric lg- and hg-MALT lymphoma
2. The durability of complete histological remission after antibiotics
3. The usefulness of pattern of NF-kB and BCL-10 by IHC staining in prospectively predicting the Hp-dependence of gastric lg- and hg-MALT lymphoma
4. The frequency of t(11;18) translocation in gastric lg- and hg-MALT lymphoma in Taiwan.
5. The association between the CYP2C18/19 genetic polymorphisms and eradication of Hp infection after antibiotics.

Conditions

  • Gastric MALT Lymphoma

Interventions

DRUG

Omeprazole, Amoxicillin, Clarithromycin

Sponsors & Collaborators

  • National Taiwan University Hospital

    collaborator OTHER

  • Tri-Service General Hospital

    collaborator OTHER

  • Chang Gung Memorial Hospital

    collaborator OTHER

  • China Medical University Hospital

    collaborator OTHER

  • Changhua Christian Hospital

    collaborator OTHER

  • Chi Mei Medical Hospital

    collaborator OTHER

  • National Health Research Institutes, Taiwan

    lead OTHER

Principal Investigators

  • Jaw-Town, Lin, M.D., PHD · Taiwan cooperative oncology group

  • Li Tzong Chen, M.D., Ph.D. · Taiwan cooperative oncology group

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00327132 on ClinicalTrials.gov